Journal of Clinical Investigation · 1991 · 108 citations · 29 references
Life SciencesHematologyImmunologyClinical ImmunologyImmunoregulationImmunotherapyBone Marrow PhysiologyHematologic DisordersImmunological Disease ModelsNeutropenia ManagementNeutrophil BiologyG-csf TherapyGranulocyte Colony-stimulating Factor AdministrationNeutralizationNeutrophil InvolvementNeutrophil Physiology
Normal dogs were treated with recombinant human granulocyte colony-stimulating factor (rhG-CSF) at 10 micrograms/kg/day for 30 d, which caused an initial neutrophilia, followed by a prolonged period of chronic neutropenia. A control dog treated with recombinant canine G-CSF (rcG-CSF) showed persistent neutrophilia over 3 mo. Serum from dogs during neutropenia contained an antibody to rhG-CSF, which neutralized the stimulatory effects of both rhG-CSF and rcG-CSF on dog marrow neutrophilic progenitor cell growth and on NFS-60 cell proliferation. 4 mo after discontinuation of rhG-CSF, the dogs' neutrophil counts returned to the normal range. Rechallenge with the rhG-CSF re-induced severe neutropenia in 1 wk. Neutropenia was transferred by plasma infusion from a neutropenic dog to a previously normal dog. These data suggest that human rhG-CSF immunizes normal dogs and thereby induces neutralization of endogenous canine G-CSF and neutropenia. This model system should allow more precise definition of the in vivo role of G-CSF.
29
Janice Gabrilove, Ann A. Jakubowski, Howard I. Scher et al. · New England Journal of Medicine · 1988 · 953 citations